Related Experiment Video
Updated: Jun 13, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
PU.1 can regulate the ZNF300 promoter in APL-derived promyelocytes HL-60
Jun-Hua Xu1, Tao Wang, Xian-Guo Wang
1State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Luojia Hill, Wuchang, Wuhan, PR China.
Abstract:
ZNF300, which plays the role in human embryonic development and some diseases, is a typical KRAB/C2H2 zinc finger gene expressed only in higher mammalians. Our data showed that expression of ZNF300 changed significantly in various leukemia blasts in the bone marrow aspirates of newly diagnosed leukemia patients. To investigate the potential relationship between expression of ZNF300 and the progression of leukemia development and hematopoietic differentiation, we cloned and characterized the putative human ZNF300 gene promoter and identified its transcription start sites (TSSs). Deletion and mutagenesis analysis demonstrated that a myeloid-specific transcription factor PU.1 binding site was responsible for myeloid-specific regulation of ZNF300 promoter activity. Furthermore, electrophoretic mobility shift and chromatin immunoprecipitation assays revealed that PU.1 bound to the PU.1 binding site within ZNF300 promoter region in vitro and in vivo. Overexpression of PU.1 elevated ZNF300 promoter activity, whereas silencing of PU.1 expression significantly reduced the activity in myeloid-derived HL-60 cell but not in T-cell Jurkat. In vitro induced HL-60 cells into CD11b expressing cells by DMSO demonstrated that ZNF300 was upregulated along with upregulation of PU.1 expression. These results demonstrated that ZNF300 was activated by PU.1 and suggested that the regulation may be involved in the progression of leukemia development and hematopoietic differentiation.
Insights
The ZNF300 gene
Area of Science:
- Molecular Biology
- Gene Regulation
- Hematopoiesis
Background:
- ZNF300 is a KRAB/C2H2 zinc finger gene involved in embryonic development and disease.
- ZNF300 expression is significantly altered in leukemia patients' bone marrow.
- Its role in leukemia progression and hematopoietic differentiation requires investigation.
Purpose of the Study:
- To investigate the relationship between ZNF300 expression and leukemia development.
- To characterize the human ZNF300 gene promoter.
- To identify regulatory mechanisms controlling ZNF300 expression.
Main Methods:
- Cloning and characterization of the ZNF300 promoter.
- Deletion and mutagenesis analysis.
- Electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) assays.
- PU.1 overexpression and silencing experiments.
- HL-60 cell differentiation studies.
Main Results:
- A myeloid-specific PU.1 binding site regulates ZNF300 promoter activity.
- PU.1 binds to the ZNF300 promoter in vitro and in vivo.
- PU.1 overexpression enhances ZNF300 promoter activity; PU.1 silencing reduces it.
- ZNF300 is upregulated during HL-60 cell differentiation, correlating with PU.1 upregulation.
Conclusions:
- ZNF300 gene expression is activated by the transcription factor PU.1.
- This PU.1-mediated regulation of ZNF300 is implicated in leukemia development and hematopoietic differentiation.
More Related Videos
Related Concept Videos
Master Transcription Regulators
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Regulation of Nuclear Protein Sorting
Abnormal Proliferation
RNA Polymerase II Accessory Proteins
Lineage Commitment

